Firebrick Pharma (ASX:FRE) — Material Events
ASX:FRE · 13 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Firebrick Targets US Pharmacy Shelves After Nasodine Online Sales SurgeHigh
Firebrick approves phased US retail pharmacy launch for Nasodine
29 Sept 2026
·Strategic Expansion and Executive Appointment
·Unexpected
·88
Firebrick’s Philippines Partner Takes Stake Above 10% in $732k PlacementMedium
Firebrick Pharma raises $732,000 with Philippines partner increasing stake above 10%
12 Oct 2026
·Capital Raising
·82
Firebrick wins Philippine OTC approval for Nasodine with Q1 2027 launch possibleMedium
Firebrick Pharma secures Philippine OTC approval for Nasodine Nasal Spray
16 Oct 2026
·Regulatory Approval
·82
Firebrick Pharma Unlocks Indonesia Market with Nasodine ApprovalMedium
Firebrick Pharma secures first regulatory approval for Nasodine in Indonesia, unlocking Southeast Asia market
27 Mar 2026
·Regulatory Approval and Partnership Agreement
·80
Firebrick Pharma Accelerates Growth with Nasodine Throat Spray Launch and 15% Sales BoostMedium
Firebrick Pharma launches Nasodine Throat Spray in Singapore, reports 15% sales growth and cost reductions
28 Jan 2026
·Quarterly Activity Report and Appendix 4C
·80
Firebrick Pharma Advances Southeast Asia Expansion with Indonesia Approval and $1.5M RaiseMedium
Firebrick Pharma achieves Indonesia approval, launches new product, raises $1.5M for expansion
21 Apr 2026
·Quarterly Activity Report
·80
Firebrick Pharma Launches Nasodine Throat Spray in Singapore, Eyes Global ExpansionMedium
Firebrick Pharma launches Nasodine Throat Spray in Singapore, plans further 2026 international rollouts
21 Jan 2026
·Product Launch Announcement
·75
Firebrick Pharma Launches Nasodine Throat Spray Amid $1.26M Half-Year LossMedium
Firebrick Pharma reports $1.26M half-year loss, launches Nasodine Throat Spray in Singapore and Fiji, eyes Philippines approval
24 Feb 2026
·Appendix 4D Half-Year Financial Report
·75
Firebrick Pharma Raises $1.5M to Fuel New Product Push and ExpansionMedium
Firebrick Pharma Raises $1.5M via Placement with Attaching Options
31 Mar 2026
·Capital Raising
·75
Firebrick Pharma Secures New Patents and Reports 43% Sales Growth Amid Stable Cash BurnMedium
Firebrick Pharma advances Nasodine commercialisation with US sales growth and Southeast Asia expansion
27 July 2026
·Investor Update
·70
Firebrick Pharma Boosts Cash Reserves, Expands Nasodine Reach in Southeast AsiaMedium
Firebrick Pharma expands Nasodine markets, reports $1.94M cash reserves after $1.4M placement
23 Oct 2025
·Quarterly Activity Report
·70
Firebrick Pharma Unveils Nasodine Throat Spray for Singapore ExportMedium
Firebrick Pharma to launch Nasodine Throat Spray for export starting November 2025
30 Oct 2025
·Product Launch Announcement
·70
No articles in this tier for the last 12 months.
Market Mentions
9
- appeared in market wrap coverage
These are market wrap articles where Firebrick Pharma (ASX:FRE) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026
3 Oct 2026
Healthcare Wrap - Week 39 (21 Sept -> 25 Sept) 2026
26 Sept 2026
Healthcare Wrap - Week 31 (27 July -> 31 July) 2026
1 Aug 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026